Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
15 pending office actions • 10 art units • 14 examiners • 0 of 15 (0%) have an AI response strategy ready • 6 patents granted in the last 365 days
Beam Therapeutics Inc. currently has 14 pending office actions within the Biotechnology & Pharmaceuticals technology area. These 14 actions are assigned to 13 distinct examiners, indicating that almost every pending matter is being reviewed by a different individual. The portfolio is also active across 10 distinct art units, which suggests that the company's applications cover a variety of specialized technical fields within the Biotechnology & Pharmaceuticals sector.
The busiest examiner for this portfolio is Yu, David Tuyang, who is currently managing 2 of the pending office actions. This concentration of 2 actions with one examiner is the only instance of overlap in the current workload, as the remaining actions are distributed among the other 13 distinct examiners. For practitioners, this means that the prosecution strategy must be tailored to the specific preferences of each individual examiner, as there is very little opportunity to apply institutional knowledge from one case to another.
The involvement of 10 distinct art units for only 14 pending office actions highlights a significant technical breadth in the company's filings. Practitioners must be prepared to navigate the different procedural nuances of these 10 distinct art units, even with a relatively small number of total actions. While Yu, David Tuyang handles 2 of the pending office actions, the overall portfolio requires a versatile approach to satisfy the requirements of the 13 distinct examiners involved.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 2 (13%) |
| §103 only | 3 (20%) |
| §112 only | 2 (13%) |
| Double-patenting + other | 5 (33%) |
| Multi-statute (no §101) | 2 (13%) |
| No statute on record | 1 (7%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| YU, DAVID TUYANG | 2 | 100.0% | +0.0% |
| DACE DENITO, ALEXANDRA GERALDINE | 1 | 56.3% | +40.2% |
| SONG, JIANFENG | 1 | 56.3% | +33.2% |
| BAEK, BONG-SOOK | 1 | 41.7% | +69.9% |
| WARD, AARON DUREL | 1 | — | — |
| HIBBERT, CATHERINE S | 1 | 58.9% | +48.8% |
| SULLIVAN, STEPHANIE LAUREN | 1 | 58.1% | +40.9% |
| YU, DELPHINUS DOU YI | 1 | 33.3% | +0.0% |
| PERSONS, JENNA L | 1 | 50.8% | +61.7% |
| NOAKES, SUZANNE MARIE | 1 | 73.3% | +18.2% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 4 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18746791 | NANOMATERIALS COMPRISING TETRAVALENT LIPID COMPOUNDS | BAEK, BONG-SOOK | — |
| 18519954 | COMPOSITIONS AND METHODS FOR THE SELF-INACTIVATION OF BASE EDITORS | YU, DAVID TUYANG | — |
| 18283148 | NOVEL CRISPR ENZYMES, METHODS, SYSTEMS AND USES THEREOF | PERSONS, JENNA L | — |
| 17265440 | MULTI-EFFECTOR NUCLEOBASE EDITORS AND METHODS OF USING SAME TO MODIFY A NUCLEIC ACID TARGET SEQUENCE | YU, DAVID TUYANG | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 7 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18460178 | USES OF ADENOSINE BASE EDITORS | NOAKES, SUZANNE MARIE | 42d overdue |
| 19649581 | METHODS AND COMPOSITIONS FOR TREATING ALPHA-1 ANTITRYPSIN DEFICIENCY | DACE DENITO, ALEXANDRA GERALDINE | — |
| 18746810 | IONIZABLE AMINE LIPIDS AND LIPID NANOPARTICLES | SONG, JIANFENG | — |
| 18746791 | NANOMATERIALS COMPRISING TETRAVALENT LIPID COMPOUNDS | BAEK, BONG-SOOK | — |
| 18515118 | BASE EDITING OF TRANSTHYRETIN GENE | HIBBERT, CATHERINE S | — |
| 18507980 | COMPOSITIONS AND METHODS FOR TREATING TRANSTHYRETIN AMYLOIDOSIS | SULLIVAN, STEPHANIE LAUREN | — |
| 18283148 | NOVEL CRISPR ENZYMES, METHODS, SYSTEMS AND USES THEREOF | PERSONS, JENNA L | — |
| Art Unit | Apps |
|---|---|
| 1635 | 4 |
| 1636 | 2 |
| 1613 | 1 |
| 1611 | 1 |
| 1658 | 1 |
| 1637 | 1 |
| 1656 | 1 |
| 1632 | 1 |
| 1600 | 1 |
| 1633 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 19649581 | METHODS AND COMPOSITIONS FOR TREATING ALPHA-1 ANTITRYPSIN DEFICIENCY | DACE DENITO, ALEXANDRA GERALDINE | 1636 | §103 | Non-Final OA | — | Pending | Apr 16, 2026 |
| 18746810 | IONIZABLE AMINE LIPIDS AND LIPID NANOPARTICLES | SONG, JIANFENG | 1613 | §102§112DP | Non-Final OA | — | Pending | Jun 18, 2024 |
| 18746791 | NANOMATERIALS COMPRISING TETRAVALENT LIPID COMPOUNDS | BAEK, BONG-SOOK | 1611 | §102§112 | Non-Final OA | — | Pending | Jun 18, 2024 |
| 18441740 | PERSISTENT ALLOGENEIC MODIFIED IMMUNE CELLS AND METHODS OF USE THEREOF | WARD, AARON DUREL | — | §102§103§112DP | Non-Final OA | — | Pending | Feb 14, 2024 |
| 18519954 | COMPOSITIONS AND METHODS FOR THE SELF-INACTIVATION OF BASE EDITORS | YU, DAVID TUYANG | 1635 | §101§103 | Non-Final OA | — | Pending | Nov 27, 2023 |
| 18515118 | BASE EDITING OF TRANSTHYRETIN GENE | HIBBERT, CATHERINE S | 1658 | §102§103DP | Non-Final OA | — | Pending | Nov 20, 2023 |
| 18507980 | COMPOSITIONS AND METHODS FOR TREATING TRANSTHYRETIN AMYLOIDOSIS | SULLIVAN, STEPHANIE LAUREN | 1635 | §103§112DP | Non-Final OA | — | Pending | Nov 13, 2023 |
| 18474969 | ADENOSINE DEAMINASE VARIANTS AND USES THEREOF | YU, DELPHINUS DOU YI | 1636 | §112 | Non-Final OA | — | Pending | Sep 26, 2023 |
| 18283148 | NOVEL CRISPR ENZYMES, METHODS, SYSTEMS AND USES THEREOF | PERSONS, JENNA L | 1637 | §101§102§103§112 | Non-Final OA | — | Pending | Sep 20, 2023 |
| 18460178 | USES OF ADENOSINE BASE EDITORS | NOAKES, SUZANNE MARIE | 1656 | Other | Non-Final OA | 42d overdue | Pending | Sep 01, 2023 |
| 17940636 | VIRAL GUIDE RNA DELIVERY | DHAR, MATASHA | 1632 | §103 | Final Rejection | — | Pending | Sep 08, 2022 |
| 17638757 | COMPOSITIONS AND METHODS FOR EDITING A MUTATION TO PERMIT TRANSCRIPTION OR EXPRESSION | KONOPKA, CATHERINE ANNE | 1635 | §103§112DP | Final Rejection | — | Pending | Feb 25, 2022 |
| 17610119 | COMPOSITIONS AND METHODS FOR TREATING HEPATITIS B | GIBBS, TERRA C | 1635 | §112 | Final Rejection | — | Pending | Nov 09, 2021 |
| 17265440 | MULTI-EFFECTOR NUCLEOBASE EDITORS AND METHODS OF USING SAME TO MODIFY A NUCLEIC ACID TARGET SEQUENCE | YU, DAVID TUYANG | 1600 | §103§112 | Final Rejection | — | Pending | Feb 02, 2021 |
| 17054393 | METHODS OF SUPPRESSING PATHOGENIC MUTATIONS USING PROGRAMMABLE BASE EDITOR SYSTEMS | POPA, ILEANA | 1633 | §103 | Final Rejection | — | Pending | Nov 10, 2020 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial